Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NBI-77860 for congenital adrenal hyperplasia in adolescent females has been withdrawn; the update references safety, pharmacokinetics a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• NBI-77860

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Congenital Adrenal Hyperplasia | Phase 1 | Status: WITHDRAWN